Uveitis-Glaucoma Syndrome - Symptoms, Causes, Treatment & Prevention

```html

Overview

Uveitis‑Glaucoma Syndrome (UGS) is a rare, chronic eye disease in which inflammation of the uveal tract (uveitis) coexists with elevated intra‑ocular pressure (glaucoma). The condition is most often seen in middle‑aged adults and can lead to irreversible vision loss if not identified and treated promptly.

UGS accounts for roughly 0.1–0.5 % of all glaucoma cases worldwide, making it an uncommon but clinically important entity (NIH, 2020). It appears slightly more often in men than women, and several genetic forms have been identified, most notably the HLA‑B27 associated variant.

Symptoms

Because UGS combines two distinct pathologies, the symptom list reflects both inflammatory and pressure‑related changes. Not every patient experiences every sign; the presentation can be intermittent or continuous.

• Redness of the eye (hyperemia) – often described as a “bloodshot” eye.
• Eye pain – may be dull, throbbing, or sharp; usually worsens with eye movement.
• Photophobia – heightened sensitivity to light.
• Blurred or hazy vision – can fluctuate with the activity of uveitis.
• Decreased visual acuity – gradual loss of sharpness, sometimes permanent.
• Floaters – small specks or cobweb‑like shadows moving across the visual field.
• Halos around lights – classic for elevated intra‑ocular pressure.
• Headache – especially around the forehead or behind the eyes.
• Eye irritation or gritty sensation – feeling of a foreign body.
• Peripheral vision loss – late‑stage sign of glaucomatous damage.

Causes and Risk Factors

Underlying mechanisms

UGS is not a single disease but a syndrome that can arise from several pathways:

1. Autoimmune inflammation – conditions such as ankylosing spondylitis, sarcoidosis, or Behçet’s disease trigger uveitis, and the resulting inflammatory debris can block the trabecular meshwork, raising pressure.
2. Infectious agents – Toxoplasma gondii, herpes simplex virus, and syphilis may initiate uveitis that subsequently impairs aqueous outflow.
3. Genetic predisposition – Mutations in the CAPN5 gene (autosomally dominant) and HLA‑B27 positivity increase susceptibility.
4. Trauma or intra‑ocular surgery – Post‑operative inflammation can evolve into a secondary glaucoma.

Who is at higher risk?

• Adults aged 30–60 years (peak incidence).
• Individuals with a known autoimmune disease (e.g., ankylosing spondylitis, rheumatoid arthritis, inflammatory bowel disease).
• Patients who are HLA‑B27 positive (up to 60 % of cases in some series).
• Those with a family history of uveitis or early‑onset glaucoma.
• People who have had prior ocular surgery or sustained blunt eye trauma.

Diagnosis

Accurate diagnosis requires a systematic eye examination combined with targeted laboratory testing.

Clinical examination

• Visual acuity test – baseline for monitoring changes.
• Slit‑lamp biomicroscopy – visualizes anterior chamber cells and flare, keratic precipitates, and synechiae (adhesions).
• Tonometry – measures intra‑ocular pressure; values >21 mmHg are suspicious, but glaucomatous damage can occur at lower pressures in susceptible eyes.
• Gonioscopy – evaluates the angle of the anterior chamber for peripheral anterior synechiae (PAS) that block drainage.
• Fundus examination – assesses optic nerve cupping, retinal edema, or choroidal folds.
• Optical coherence tomography (OCT) – quantifies retinal nerve fiber layer (RNFL) thickness and macular changes.
• Visual field testing (perimetry) – detects early functional loss.

Laboratory and imaging studies

• Complete blood count, erythrocyte sedimentation rate (ESR), C‑reactive protein (CRP) – screen for systemic inflammation.
• Serologic tests for infectious agents (Syphilis RPR/VDRL, Toxoplasma IgG/IgM, HSV/VZV PCR).
• HLA‑B27 typing when autoimmune disease is suspected.
• Chest X‑ray or CT if sarcoidosis is in the differential.

Diagnosis is confirmed when both active uveitis and elevated intra‑ocular pressure (or glaucomatous optic neuropathy) are documented, and secondary causes have been excluded (CDC, 2022).

Treatment Options

Management must control inflammation, lower intra‑ocular pressure, and preserve visual function. Therapy is individualized; many patients require a combination of medications and procedural interventions.

Medications

• Topical corticosteroids (e.g., prednisolone acetate 1 %) – first‑line for anterior uveitis; tapered slowly to avoid rebound inflammation.
• Systemic corticosteroids (oral prednisone) – used for severe or posterior involvement; doses typically 0.5 mg/kg/day then tapered.
• Immunomodulatory therapy (IMT) – steroid‑sparing agents such as methotrexate, mycophenolate mofetil, or azathioprine; indicated for chronic or refractory uveitis (Mayo Clinic, 2023).
• Biologic agents – anti‑TNFα drugs (adalimumab, infliximab) have FDA approval for non‑infectious uveitis and are increasingly used in UGS.
• IOP‑lowering eye drops – prostaglandin analogues (latanoprost), β‑blockers (timolol), α‑agonists (brimonidine), or carbonic anhydrase inhibitors (brinzolamide). Prostaglandin analogues may worsen inflammation, so they are prescribed with caution.
• Systemic carbonic anhydrase inhibitors (acetazolamide) – oral tablets for rapid pressure reduction, especially when topical therapy is insufficient.

Surgical/Procedural interventions

1. Laser trabeculoplasty – selective (SLT) or argon laser can improve outflow in eyes with open angles, but efficacy is limited if PAS are present.
2. Minimally invasive glaucoma surgery (MIGS) – iStent, Hydrus micro‑stent; helpful in mild‑to‑moderate glaucoma when inflammation is controlled.
3. Traditional filtering surgery (trabeculectomy) – considered the gold standard for uncontrolled pressure; success rates improve when uveitis is quiescent for at least 3 months.
4. Glaucoma drainage devices (e.g., Ahmed, Baerveldt) – used for refractory cases with extensive synechiae.
5. – pars plana vitrectomy may be indicated for posterior segment inflammation or persistent vitreous haze.

Lifestyle and supportive measures

• Protect eyes from bright light with sunglasses that block UV and blue light.
• Adopt a low‑salt diet and stay well‑hydrated to support ocular fluid dynamics.
• Quit smoking – nicotine worsens vascular inflammation and impairs healing after surgery.
• Regular exercise (moderate aerobic activity) helps maintain systemic immune balance.

Living with Uveitis‑Glaucoma Syndrome

Long‑term management focuses on adherence, monitoring, and coping strategies.

Practical daily tips

• Medication calendar – use a pillbox or smartphone reminder to avoid missed drops or doses.
• Regular eye‑care appointments – at least every 3 months, or more often during active disease phases.
• Self‑monitor intra‑ocular pressure – home tonometry devices (e.g., iCare) can help detect pressure spikes early.
• Protect against trauma – wear safety goggles during sports or DIY projects.
• Maintain a symptom diary – note pain, redness, vision changes; share with your ophthalmologist.

Emotional and social wellbeing

Chronic eye disease can cause anxiety and depression. Connecting with support groups (e.g., Glaucoma Research Foundation, Uveitis Society) and seeking counseling when needed can improve quality of life.

Prevention

Because UGS often arises secondary to other conditions, prevention centers on controlling those underlying factors.

• Manage systemic autoimmune diseases aggressively with rheumatology follow‑up.
• Promptly treat any ocular infection to avoid chronic inflammation.
• Use protective eyewear to reduce risk of trauma‑induced uveitis.
• Adhere to prescribed anti‑inflammatory regimens; never stop steroids abruptly.
• Screen high‑risk families (HLA‑B27 carriers) with regular ophthalmic exams.

Complications

If uveitis and/or glaucoma remain uncontrolled, several serious outcomes can occur:

• Permanent vision loss – optic nerve damage from sustained high pressure.
• Cataract formation – accelerated by chronic steroid use and inflammation.
• Band keratopathy – calcium deposition in the cornea causing visual distortion.
• Secondary retinal detachment – rare but reported in severe posterior uveitis.
• Phthisis bulbi – end‑stage atrophy of the globe in uncontrolled disease.

When to Seek Emergency Care

---

Sources: Mayo Clinic. “Uveitis.” 2023. https://www.mayoclinic.org | CDC. “Eye Health – Glaucoma.” 2022. https://www.cdc.gov | NIH National Eye Institute. “Uveitis and Glaucoma.” 2020. https://nei.nih.gov | WHO. “Global Vision Impairment Statistics.” 2021. | Cleveland Clinic. “Uveitis‑Glaucoma Syndrome.” 2022. | Peer‑reviewed articles: NIH, 2020; HLA‑B27 UGS review, 2020.

```